Connecticut Innovations (CI), the quasi-public state agency that provides venture capital for startups, paused its second annual Tour de Connecticut on Tuesday to celebrate its biggest bioscience wins ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from ...

British pharma giant AstraZeneca plans to spend $135 million to expand the manufacturing operations footprint of its site in Södertälje, Sweden, by 50%. The project calls for a 2,700-square ...

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could raise additional doubts around the first-in-class AKT inhibitor.

LONDON, Sept 9 (Reuters) - Detailed results from one of AstraZeneca's (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not ...

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the British drugmaker’s experimental lung cancer medicine with partner ...

Welcome, ladies and gentlemen, to AstraZeneca's Investor Conference Call ESMO 2024. Before I hand over to AstraZeneca's management team, I'd like to read the safe harbor statement. The Company ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.

Qiagen and AstraZeneca are expanding their diagnostics partnership, with plans to explore the use of genomic profiling in chronic diseases beyond cancer. The long-time collaborators, which ...

Sept 16 (Reuters) - Sanofi (SASY.PA), opens new tab and partner AstraZeneca (AZN.L), opens new tab have received approval from the U.S. Food and Drug Administration for a manufacturing line for ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...